Research programme: B-cell disorder therapeutics - Thunderbolt Pharma
Latest Information Update: 09 Jun 2016
At a glance
- Originator Astellas Pharma
- Developer Thunderbolt Pharma
- Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders